Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
2.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

PMID:
28334439
3.

Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases.

Arnason T, Borger DR, Corless C, Hagen C, Iafrate AJ, Makhlouf H, Misdraji J, Sapp H, Tsui WM, Wanless IR, Zuluaga Toro T, Lauwers GY.

Am J Surg Pathol. 2017 Apr;41(4):499-505. doi: 10.1097/PAS.0000000000000773.

PMID:
28266931
4.

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX.

Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13.

PMID:
28192597
5.

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.

Strickland MR, Gill CM, Nayyar N, D'Andrea MR, Thiede C, Juratli TA, Schackert G, Borger DR, Santagata S, Frosch MP, Cahill DP, Brastianos PK, Barker FG 2nd.

J Neurosurg. 2017 Aug;127(2):438-444. doi: 10.3171/2016.8.JNS161076. Epub 2016 Nov 25.

PMID:
27885953
6.

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

Lennerz JK, van der Sloot KW, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park DY, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, Iafrate AJ, Lauwers GY.

Int J Colorectal Dis. 2016 May;31(5):973-82. doi: 10.1007/s00384-016-2574-x. Epub 2016 Mar 30.

PMID:
27026089
7.

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.

Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ.

Gynecol Oncol. 2016 Apr;141(1):108-12. doi: 10.1016/j.ygyno.2016.02.032.

PMID:
27016236
8.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

9.

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V.

J Mol Diagn. 2015 Nov;17(6):661-8. doi: 10.1016/j.jmoldx.2015.06.004. Epub 2015 Aug 30.

10.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

11.

Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR).

Dong F, Kojiro S, Borger DR, Growdon WB, Oliva E.

Am J Surg Pathol. 2015 Aug;39(8):1045-53. doi: 10.1097/PAS.0000000000000454.

PMID:
26171917
12.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

13.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA.

Nat Commun. 2015 Mar 11;6:6377. doi: 10.1038/ncomms7377.

14.

Microsatellite instability in gallbladder carcinoma.

Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V.

Virchows Arch. 2015 Apr;466(4):393-402. doi: 10.1007/s00428-015-1720-0. Epub 2015 Feb 14.

PMID:
25680569
15.

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR.

Gynecol Oncol. 2015 Apr;137(1):160-6. doi: 10.1016/j.ygyno.2015.01.533. Epub 2015 Jan 17.

16.

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.

Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7.

17.

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.

Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, Borger DR, McAfee SL, Kroshinsky D, Chen YB.

J Clin Oncol. 2016 Mar 10;34(8):e70-2. doi: 10.1200/JCO.2013.50.7582. Epub 2014 Jul 14. No abstract available.

PMID:
25024084
18.

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX.

Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24.

19.

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.

Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM.

Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3.

20.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

21.

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR.

Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23.

22.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

23.

Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.

Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z.

PLoS One. 2014 Apr 2;9(4):e93996. doi: 10.1371/journal.pone.0093996. eCollection 2014.

24.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

25.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

26.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.

Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS.

Ann Oncol. 2014 Jan;25(1):121-6. doi: 10.1093/annonc/mdt516.

27.

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.

Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN.

Genes Chromosomes Cancer. 2014 Jan;53(1):67-77. doi: 10.1002/gcc.22118. Epub 2013 Nov 5.

PMID:
24249259
28.

BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas.

Cipriani NA, Letovanec I, Hornicek FJ, Mullen JT, Duan Z, Borger DR, Nielsen GP.

Histopathology. 2014 Apr;64(5):639-46. doi: 10.1111/his.12305. Epub 2013 Dec 7.

PMID:
24117833
29.

Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.

Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS.

J Gastrointest Cancer. 2014 Mar;45(1):34-9. doi: 10.1007/s12029-013-9546-y.

30.

Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding.

Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E.

N Engl J Med. 2013 May 9;368(19):1827-35. doi: 10.1056/NEJMcpc1209276. No abstract available.

PMID:
23656649
31.

Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.

Kerr DA, Lopez HU, Deshpande V, Hornicek FJ, Duan Z, Zhang Y, Rosenberg AE, Borger DR, Nielsen GP.

Am J Surg Pathol. 2013 Jun;37(6):787-95. doi: 10.1097/PAS.0b013e31827ab703.

PMID:
23598960
32.

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults.

Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN.

J Clin Oncol. 2013 May 10;31(14):e233-6. doi: 10.1200/JCO.2012.46.0220. Epub 2013 Apr 1. No abstract available.

PMID:
23547069
33.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

34.

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB.

Blood. 2012 Nov 29;120(23):4649-52. doi: 10.1182/blood-2012-06-438267. Epub 2012 Oct 16.

35.

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.

Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS.

Gynecol Oncol. 2012 Oct;127(1):141-6. doi: 10.1016/j.ygyno.2012.06.028. Epub 2012 Jun 26.

PMID:
22750258
36.

IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.

Borger DR, Zhu AX.

Expert Rev Anticancer Ther. 2012 May;12(5):543-6. doi: 10.1586/era.12.32. No abstract available.

PMID:
22594888
37.

Activation of PI3K signaling in Merkel cell carcinoma.

Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D.

Clin Cancer Res. 2012 Mar 1;18(5):1227-36. doi: 10.1158/1078-0432.CCR-11-2308. Epub 2012 Jan 18.

38.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

39.

Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.

McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR.

PLoS One. 2011;6(11):e28077. doi: 10.1371/journal.pone.0028077. Epub 2011 Nov 29.

40.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D.

Ann Oncol. 2011 Dec;22(12):2616-24. doi: 10.1093/annonc/mdr489. Epub 2011 Nov 9.

41.

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.

Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP.

Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27.

42.

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S.

PLoS One. 2011 Mar 29;6(3):e17948. doi: 10.1371/journal.pone.0017948.

43.

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W.

J Mol Diagn. 2011 Jan;13(1):74-84. doi: 10.1016/j.jmoldx.2010.11.010. Epub 2010 Dec 23.

44.

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.

Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR.

Gynecol Oncol. 2011 Apr;121(1):212-7. doi: 10.1016/j.ygyno.2010.11.039. Epub 2010 Dec 17.

PMID:
21168197
45.

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.

Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR.

Reprod Biol Endocrinol. 2010 Dec 1;8:147. doi: 10.1186/1477-7827-8-147.

46.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.

J Clin Oncol. 2010 Nov 20;28(33):4953-60. doi: 10.1200/JCO.2010.30.8338. Epub 2010 Oct 12.

47.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.

Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.

EMBO Mol Med. 2010 May;2(5):146-58. doi: 10.1002/emmm.201000070.

48.

Decreased survival in EGFR gene amplified vulvar carcinoma.

Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR.

Gynecol Oncol. 2008 Nov;111(2):289-97. doi: 10.1016/j.ygyno.2008.07.038. Epub 2008 Sep 3.

PMID:
18768215
49.

AMP-activated protein kinase is essential for survival in chronic hypoxia.

Borger DR, Gavrilescu LC, Bucur MC, Ivan M, Decaprio JA.

Biochem Biophys Res Commun. 2008 May 30;370(2):230-4. doi: 10.1016/j.bbrc.2008.03.056. Epub 2008 Mar 24.

50.

Supplemental Content

Loading ...
Support Center